Join Here   |   Log In

Tamiflu: Genetic Reasons it May not Work for You

Every year about 3 to 5 million people get the flu, and this results in about 250,000 to 500,000 deaths worldwide.[ref] One common prescription medication for the flu is Tamiflu, also known as oseltamivir. There are a couple of genetic variants that influence the way that oseltamivir works.

Fighting flu symptoms with Tamiflu

Influenza is an RNA virus and is divided into the genera: influenza A, B, and C. Influenza A is usually the worst form. Different strains of influenza A and B circulate worldwide each year.

Viruses in general:

Viruses are not classified by biologists as ‘alive’ because they cannot replicate outside of a host cell. First, they must enter a living organism (e.g., humans). Then they move into a cell via a cell membrane receptor. Finally, the virus hijacks the host cell’s ability to transcribe RNA (or DNA) into the proteins needed for the virus to replicate. After the virus replicates, the new viruses are released from the cell, moving on to infect other cells.

Flu virus replication and release:

The influenza viruses are all enveloped viruses. This means that they are surrounded by a lipid envelope. The envelope is actually formed from the host cell’s membrane when the virus is released after replicating in the cell.

Sticking out of the surface envelope of the flu virus, there are two types of glycoproteins. One of these proteins, called neuraminidase, is used by the replicated virus to cause the release out of the host cell. Inhibiting neuraminidase, therefore, stops the release of the replicated viruses and decreases the rate at which it can spread in the body.[ref]

Tamiflu is a neuraminidase inhibitor

Oseltamivir (Tamiflu) is an antiviral drug that is used for the prevention and treatment of the flu. It is in a class of drugs called neuraminidase inhibitors. Other FDA-approved neuraminidase inhibitors include zanamivir (Relenza).

Side effects:

A small minority of people may have significant central nervous system orneuropsychiatric-relatedd side effects from oseltamivir. In Japan, it is now considered ‘counter-indicative’ to give oseltamivir to children aged 10-19 due to concerns that it can cause abnormal behavior or sudden death. Causation has not been proven, though, according to other studies. The abnormal behavior seen in teens included neuropsychiatric adverse reactions such as hallucinations and psychotic symptoms, as well as low body temperature.[ref][ref]

A Cochrane review found that there is a risk for QT prolongation (heart problem), psychiatric disorders, kidney problems, and high blood sugar with oseltamivir. Animal studies back up a lot of these side effects and explain the mechanism of action for everything except for the metabolic effect.[ref]

Conversion into the active drug:

Oseltamivir (Tamiflu) is a prodrug that has to be metabolized by CES1 into the active drug in the body. Some people have genetic variants that decrease the function of the CES1 enzyme.

Women naturally seem to have greater CES1 activity than men, so the effects of the genetic variant may be intensified for men.


Tamiflu Genotype Report:

Members: Log in to see your data below.
Not a member? Join here. Membership lets you see your data right in each article and also gives you access to the member’s only information in the Lifehacks sections.

ABCB1 Genetic Variants:

In addition to the conversion of oseltamivir into the active component by CES1, there is another genetic component that comes into play here. The ABCB1 gene codes for a transporter that moves foreign substances back out of a cell. This is a process that works well and makes sense – the cells need to spit the toxins back out. But, when it comes to medications, the ABCB1 genetic variants that increase the activity of the gene can actually be a problem.

CES1
rs71647871   (↗️ dbSNP)
CCtypicalyour genotype
CT60% decreased CES1 enzyme function;your genotype
TTmore than 60% decreased CES1 (rare genotype)your genotype

Your genotype for rs71647871 is — (not in your raw data).

Research & references
    CES1
    rs121912777   (↗️ dbSNP)
    CCtypicalyour genotype
    CTsignificantly decreased CES1 enzyme function (rare genotype)your genotype
    TTsignificantly decreased CES1 (rare genotype)your genotype

    Your genotype for rs121912777 is — (not in your raw data).

    Research & references
      ABCB1
      rs1045642   (↗️ dbSNP)
      GGgreater efflux (out of the cell) for drugs and toxins, no increase in adverse events with oseltamiviryour genotype
      AGintermediate efflux, no increase in adverse events with oseltamiviryour genotype
      AAreduced drug efflux (out of the cell), may need lower dosages of some drugs in comparison to those with GG Increased risk of adverse events with oseltamiviryour genotype

      Your genotype for rs1045642 is — (not in your raw data).

      Research & references


        Lifehacks:

        Understand the medications available for the flu before you get it… When you have the flu and feel terrible, you aren’t going to be able to think and make rational decisions.

        The rest of this article is for Genetic Lifehacks members only. Consider joining today to see the rest of this article.

        Access this content:

        An active subscription is required to access this content.

        Join as a member



        Related Articles and Topics:

        Genetic Susceptibility to Viruses

        Circadian Rhythm and Your Immune Response to Viruses


        References:

        Bermúdez de León, Mario, et al. “Association Study of Genetic Polymorphisms in Proteins Involved in Oseltamivir Transport, Metabolism, and Interactions with Adverse Reactions in Mexican Patients with Acute Respiratory Diseases.” The Pharmacogenomics Journal, vol. 20, no. 4, Aug. 2020, pp. 613–20. PubMed, https://doi.org/10.1038/s41397-020-0151-8.
        Hama, Rokuro. “The Mechanisms of Delayed Onset Type Adverse Reactions to Oseltamivir.” Infectious Diseases (London, England), vol. 48, no. 9, Sept. 2016, pp. 651–60. PubMed Central, https://doi.org/10.1080/23744235.2016.1189592.
        Han, Nayoung, et al. “Assessment of Adverse Events Related to Anti-Influenza Neuraminidase Inhibitors Using the FDA Adverse Event Reporting System and Online Patient Reviews.” Scientific Reports, vol. 10, Feb. 2020, p. 3116. PubMed Central, https://doi.org/10.1038/s41598-020-60068-5.
        Laborda, Pedro, et al. “Influenza Neuraminidase Inhibitors: Synthetic Approaches, Derivatives and Biological Activity.” Molecules, vol. 21, no. 11, Nov. 2016, p. 1513. PubMed Central, https://doi.org/10.3390/molecules21111513.
        Maxwell, Simon R. J. “Tamiflu and Neuropsychiatric Disturbance in Adolescents.” BMJ : British Medical Journal, vol. 334, no. 7606, June 2007, pp. 1232–33. PubMed Central, https://doi.org/10.1136/bmj.39240.497025.80.
        Shi, Jian, et al. “Association of Oseltamivir Activation with Gender and Carboxylesterase 1 Genetic Polymorphisms.” Basic & Clinical Pharmacology & Toxicology, vol. 119, no. 6, Dec. 2016, pp. 555–61. PubMed, https://doi.org/10.1111/bcpt.12625.
        Shon, Ji-Hong, et al. “Effect of Itraconazole on the Pharmacokinetics and Pharmacodynamics of Fexofenadine in Relation to the MDR1 Genetic Polymorphism.” Clinical Pharmacology and Therapeutics, vol. 78, no. 2, Aug. 2005, pp. 191–201. PubMed, https://doi.org/10.1016/j.clpt.2005.04.012.
        Tarkiainen, E. K., et al. “Carboxylesterase 1 Polymorphism Impairs Oseltamivir Bioactivation in Humans.” Clinical Pharmacology and Therapeutics, vol. 92, no. 1, July 2012, pp. 68–71. PubMed, https://doi.org/10.1038/clpt.2012.13.
        Yi, So-Young, et al. “A Variant 2677A Allele of the MDR1 Gene Affects Fexofenadine Disposition.” Clinical Pharmacology and Therapeutics, vol. 76, no. 5, Nov. 2004, pp. 418–27. PubMed, https://doi.org/10.1016/j.clpt.2004.08.002.

        About the Author:
        Debbie Moon is a biologist, engineer, author, and the founder of Genetic Lifehacks where she has helped thousands of members understand how to apply genetics to their diet, lifestyle, and health decisions. With more than 10 years of experience translating complex genetic research into practical health strategies, Debbie holds a BS in engineering from Colorado School of Mines and an MSc in biological sciences from Clemson University. She combines an engineering mindset with a biological systems approach to explain how genetic differences impact your optimal health.